Circulating Tumor DNA in Peripheral T-cell Lymphomas

Summary

The aim of this study is to evaluate the feasibility of circulating tumor DNA (ctDNA) measurement in blood plasma for the applicability in prognostication, treatment evaluation and measurable residual disease (MRD) surveillance in a cohort of patients with newly diagnosed or relapsed/refractory peripheral T-cell lymphomas (PTCL).

Eligibility

Inclusion Criteria:

* Patients with newly diagnosed or relapsed/refractory peripheral T-cell lymphoma.
* All primary systemic PTCL entities from the International Consensus Classification 2022.
* ≥18 years of age.
* Life expectancy of 3 months or longer.
* ECOG performance status 0-4 at study entry (PS4 only if lymphoma-induced).
* Measurable disease.
* Written informed consent.

Exclusion Criteria:

* T-cell prolymphocytic leukemia
* T-cell large granular lymphocytic leukemia
* Chronic lymphoproliferative disorder of NK cells
* Adult T-cell leukemia / lymphoma
* Aggressive NK-cell leukemia
* Primary cutaneous T-cell lymphoma such as Sézary syndrome and Mycosis fungoides.
* Primary cutaneous CD30 positive T-cell lymphoproliferative disorders.
* Lymphomatoid papulosis.
* Primary cutaneous anaplastic large cell lymphoma.
* Primary cutaneous small/medium CD4-positive T-cell lymphoproliferative disorder.
* Primary cutaneous gamma-delta T-cell lymphoma.
* Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder.
* Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma.
* History of active cancer during the past year, except basal cell carcinoma of the skin or stage 0 cervical carcinoma (in situ).
* Unwillingness or inability to comply with the study protocol.

Conditions3

Browse More Trials